Terns Pharmaceuticals, Inc. (TERN)
2025-06-30 | ||||
|---|---|---|---|---|
| Income tax expense | 64 | |||
| Research and development | 20,353 | |||
| General and administrative | 7,030 | |||
| Total operating expenses | 27,383 | |||
| Loss from operations | -27,383 | |||
| Other income (expense), net | 4 | |||
| Interest income | 3,350 | |||
| Total other income, net | 3,354 | |||
| Loss before income taxes | -24,029 | |||
| Net loss | -24,093 | |||
| Earnings per share, basic, total | -0.26 | |||
| Earnings per share, diluted, total | -0.26 | |||
| Weighted average number of shares outstanding, basic, total | 91,575,039 | |||
| Weighted average number of shares outstanding, diluted, total | 91,575,039 | |||